Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
Why Is IRIDEX Corporation (IRIX) Stock Down -28.53% Today?

Why Is IRIDEX Corporation (IRIX) Stock Down -28.53% Today?

Key Takeaways

  • IRIX shares dropped 28.53% to $0.50 in Wednesday morning trading, extending a slide that began in Tuesday's after-hours session from a $0.6996 close.
  • The primary catalyst was a third-quarter report that missed on both revenue and earnings, with revenue of $10.2 million against roughly $12.65 million expected and a loss of $0.08 per share versus a $0.02 loss consensus.
  • Secondary drivers included a cut to full-year 2026 revenue guidance to $46–$48 million from $51–$53 million and a decline in cash to $3.7 million.
  • Broader medical-device and healthcare benchmarks were only modestly lower, making the decline overwhelmingly company-specific rather than sector-driven.
  • News Significance Score: 81/100 — a major earnings and guidance shock amplified by an unusually violent price reaction.
  • Traders are watching the implied fourth-quarter revenue range of roughly $11.5–$13.5 million, the company's cash position, and progress on European regulatory clearance.
  • Deeper detail on Price Targets, Earnings, and Forecast pages is available for readers who want to dig into the numbers behind the move.
  • Readers can also explore Trending AI Robots to see which automated strategies are performing best in the current market.

Opening Summary

IRIDEX Corporation (IRIX) is a small-cap medical technology company that develops laser consoles, delivery devices and disposable probes used in ophthalmology, with its core franchises in glaucoma (the Cyclo G6 and MicroPulse P3 platform) and retinal surgery (the PASCAL line). In late-morning trading Wednesday, the stock changed hands at $0.50, down 28.53% from the prior session's close of $0.6996 — a decisive move lower. The immediate reason is unambiguous: the company reported third-quarter 2026 results after Tuesday's close that fell well short of expectations on revenue and earnings and included a reduced full-year outlook.

Q3 Revenue Miss and Guidance Cut

The quarter ended October 3 produced revenue of $10.2 million, down about 19% from $12.5 million a year earlier and materially below the roughly $12.65 million consensus. The shortfall was concentrated overseas. International retina sales weakened across China, Japan and Europe, with China orders collapsing to about $400,000 from roughly $4 million a year earlier. Global Cyclo G6 probe volume slipped to approximately 11,900 units from 14,900, and system placements eased to 28 from 30. Management blamed order timing, distributor destocking ahead of the manufacturing relocation, and regulatory delays.

Earnings quality followed the top line. The GAAP net loss was $1.4 million, or $0.08 per share, wider than the $0.02 loss analysts modeled, and adjusted EBITDA swung to a loss of $0.6 million from $0.1 million a year earlier. Management cut its full-year 2026 revenue guidance to $46–$48 million from $51–$53 million, a reduction of roughly 10% at the midpoint, citing continued international volatility and regulatory timing. For a company valued near $9 million at today's price, a revision of that size is a major event rather than a routine update.

Cash Burn and Balance-Sheet Scrutiny

The cash picture reinforced the selling. Cash and equivalents fell to $3.7 million from $4.7 million at the end of the second quarter, and operating cash use was about $1 million as inventories swelled to $11.8 million to protect distributors during the facility transition. Total liabilities stood at $26.6 million against total assets of $29.3 million. With a thin cash cushion and an ongoing loss profile, the market is pricing dilution and financing risk more aggressively than the operating miss alone would justify.

The Overlooked Bull Case

Not every data point was negative, which is why the reaction is notable. Gross margin climbed to 42.4% from 32.1% a year earlier, a ten-point year-over-year improvement, helped by favorable geographic mix and pricing discipline. U.S. PASCAL revenue rose approximately 50% year over year, U.S. glaucoma pricing firmed, and the San Jose manufacturing relocation is complete, expected to deliver roughly $600,000 in annualized rent savings. Management is also conducting a strategic review of its product portfolio and distribution footprint and targets meaningful margin expansion and operating expense reductions in 2027. Investors are evidently unwilling to pay for that optionality while the revenue base is shrinking.

Market Context and Trading Activity

Volume was heavy. Roughly 160,000 shares had changed hands within the first 90 minutes of Wednesday's session, several times the stock's recent daily average of roughly 28,000–50,000 shares. The stock gapped open at $0.50 and traded in a range of about $0.47 to $0.53, putting it at its lowest levels of the past three months and roughly 30% below its 50-day average near $0.71. The move was not a sector event: a broad medical-device benchmark slipped about 0.3% and the large healthcare sector ETF fell about 1.6%, so the decline is idiosyncratic rather than a sympathy selloff. Analyst coverage is thin, with a single published rating, which tends to amplify post-earnings repricing in micro-caps.

News Significance Score

On a scale where 0 means no meaningful news and a move that is normal for the stock, and 100 means transformative news paired with an extreme, rare price move, IRIX scores 81 out of 100. The verified news was substantial: revenue and earnings both missed consensus and full-year guidance was cut by about 10% at the midpoint, a large revision for a company of this size. The reaction was equally unusual — today's 28.5% decline is roughly ten times the stock's typical 2.7% absolute daily move, and no single-session drop of comparable size has occurred in the past 60 sessions, where the worst was 8.7%.

What Comes Next for IRIX

Attention turns to the fourth quarter, which management expects to benefit from the release of remaining safety stock, deferred Japan PASCAL shipments worth about $300,000, open international orders and typical year-end seasonality. The lowered guidance implies quarterly revenue in the rough area of $11.5–$13.5 million, and management has said sequential and year-over-year growth in both probes and systems is expected. Key swing factors include European PASCAL MDR certification, now targeted for the first half of 2027, the pace of the contract-manufacturing transition, further operating expense reductions, and whether the strategic review results in portfolio exits. Principal risks are continued weakness in China, competitive pricing pressure in Europe, and the adequacy of a $3.7 million cash balance against an $11.8 million inventory position.

Trending AI Robots

Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions make it into the curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics and the specific symbols they trade, so the lineup rotates as market conditions shift. Investors looking for systematic, rules-based exposure can review the current leaders and compare approaches before deciding which fits their own objectives.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IRIX

Contributor

Dem Sem's AvatarDem Sem|Expert

IRIX in upward trend: price may jump up because it broke its lower Bollinger Band on November 06, 2026

IRIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 49 cases where IRIX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 67 cases where IRIX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on IRIX as a result. In 73 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.

Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRIX advanced for three days, in 150 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

Bearish Trend Analysis

The 10-day RSI Indicator for IRIX moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 22 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.

The Moving Average Convergence Divergence Histogram (MACD) for IRIX turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 36 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

IRIX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IRIX crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

The Aroon Indicator for IRIX entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.955) is normal, around the industry mean (4.142). P/E Ratio (-3.330) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (3.870) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.204) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. IRIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -9%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -14%. POAS experienced the highest price growth at 172%, while LFWD experienced the biggest fall at -46%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -44%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was -49%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 62
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of light-based medical systems and delivery devices

Industry MedicalNursingServices

Industry
Medical Specialties
Address
1212 Terra Bella Avenue
Phone
+1 650 940-4700
Employees
108
Web
https://www.iridex.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.